End-of-day quote
OTC Bulletin Board
|
5-day change
|
1st Jan Change
|
- USD
|
-.--%
|
|
-.--%
|
-.--%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
19.23
|
24.72
|
23.43
|
23.07
|
45.43
|
40.27
|
Enterprise Value (EV)
1 |
33.11
|
44.5
|
47.13
|
24.13
|
47.59
|
43.22
|
P/E ratio
|
-2.34
x
|
-3.54
x
|
-3.44
x
|
-4.05
x
|
-12.8
x
|
-13
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
45,934,892
x
|
72,213,378
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
48,121,944
x
|
77,502,175
x
|
EV / EBITDA
|
-4.51
x
|
-8.12
x
|
-10
x
|
-5.21
x
|
-14.1
x
|
-17.4
x
|
EV / FCF
|
-9.47
x
|
-11.7
x
|
44.5
x
|
-3.48
x
|
-39.6
x
|
-37.2
x
|
FCF Yield
|
-10.6%
|
-8.52%
|
2.25%
|
-28.8%
|
-2.53%
|
-2.68%
|
Price to Book
|
-1.1
x
|
-1.03
x
|
-0.77
x
|
-5.48
x
|
-7.27
x
|
-5.29
x
|
Nbr of stocks (in thousands)
|
384,615
|
389,889
|
401,232
|
419,447
|
419,497
|
419,522
|
Reference price
2 |
0.0500
|
0.0634
|
0.0584
|
0.0550
|
0.1083
|
0.0960
|
Announcement Date
|
3/7/19
|
3/5/20
|
3/2/21
|
3/29/22
|
3/30/23
|
3/28/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
-
|
-
|
0.989
|
0.5577
|
EBITDA
1 |
-7.343
|
-5.48
|
-4.694
|
-4.628
|
-3.38
|
-2.489
|
EBIT
1 |
-8.028
|
-6.166
|
-4.936
|
-4.641
|
-3.391
|
-2.498
|
Operating Margin
|
-
|
-
|
-
|
-
|
-342.86%
|
-447.97%
|
Earnings before Tax (EBT)
1 |
-8.153
|
-6.923
|
-6.678
|
-5.54
|
-3.555
|
-3.102
|
Net income
1 |
-8.153
|
-6.923
|
-6.678
|
-5.54
|
-3.555
|
-3.102
|
Net margin
|
-
|
-
|
-
|
-
|
-359.41%
|
-556.16%
|
EPS
2 |
-0.0213
|
-0.0179
|
-0.0170
|
-0.0136
|
-0.008474
|
-0.007393
|
Free Cash Flow
1 |
-3.497
|
-3.793
|
1.059
|
-6.94
|
-1.202
|
-1.161
|
FCF margin
|
-
|
-
|
-
|
-
|
-121.52%
|
-208.09%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/7/19
|
3/5/20
|
3/2/21
|
3/29/22
|
3/30/23
|
3/28/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
13.9
|
19.8
|
23.7
|
1.06
|
2.16
|
2.95
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-1.89
x
|
-3.61
x
|
-5.049
x
|
-0.2293
x
|
-0.6399
x
|
-1.185
x
|
Free Cash Flow
1 |
-3.5
|
-3.79
|
1.06
|
-6.94
|
-1.2
|
-1.16
|
ROE (net income / shareholders' equity)
|
59.4%
|
33.4%
|
24.6%
|
32.2%
|
68.3%
|
44.9%
|
ROA (Net income/ Total Assets)
|
-185%
|
-222%
|
-299%
|
-141%
|
-76.4%
|
-89.6%
|
Assets
1 |
4.407
|
3.112
|
2.236
|
3.918
|
4.655
|
3.462
|
Book Value Per Share
2 |
-0.0500
|
-0.0600
|
-0.0800
|
-0.0100
|
-0.0100
|
-0.0200
|
Cash Flow per Share
2 |
0
|
0
|
0
|
0
|
0
|
0
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/7/19
|
3/5/20
|
3/2/21
|
3/29/22
|
3/30/23
|
3/28/24
|
|
1st Jan change
|
Capi.
|
---|
| -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|